In Pursuit of Disruptive
Anti-Aging Drugs
Genflow Biosciences Ltd is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the aging process in humans and dogs.
The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.
Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that clinical trials will continue at pace in the next 24 months.
Transformative Medicine – Compassionate Medicine
Aging is not a natural fatality. There is no rationale for a limited lifespan. Ethically, aging shoould now be considered as a risk factor that we can treat. By treating aging, we believe that Genflow Biociences can contribute to decrease healthcare costs and lessen the emotional and societal burden that comes with an aging population.
Intellectually Curious
We see aging as a natural multi-factorial process that can be treated
Collaborative
We have partnerships with highly experienced research centers and longevity funds
Innovative
We are using most recent gene delivery tools to safely provide extra copies of SIRT6 gene to control aging
Ethical
We conduct solid preclinical research foundations to support clinical testing
Considerate
We are dedicated to decrease the societal burden that comes with an aging population
Courageous
We want to be the first company to create a disruptive anti-aging drug via our lead candidate GF-1002
Increased Life Expectancy
According to the United Nations the proportion of the world aged over 65 is set to rise from 9.3% in 2020 to reach 22.6% by 2100
Increased Health Expenditure
Due To Aging
The OECD [1] estimates that health expenditure will rise from 8.8% of GDP in 2015 to 10.2% by 2030
Slowing Aging Opportunity
For the US it has been estimated that the benefits of slowing ageing such that life expectancy increases by between one and two years is worth between $7trillion and $38trillion [2]
[2] D. P. Goldman, D. Cutler, J. W. Rowe, P.-C. Michaud, J. Sullivan, D. Peneva, and S. J. Olshansky. Substantial Health And Economic Returns From Delayed Aging MayWarrant A New Focus For Medical. Research. Health A_airs (Millwood), 32(10):1698{1705, Oct. 2013. And A.J.Scott, M.Ellison and D.A.Sinclair “The Economic Value of Targeting Aging”, Nature Ageing, forthcoming.